Urban hype

From pharmacy to high street: How GLP 1s are reshaping the UK and what pharma must prepare for next chapter

GLP-1 therapies have now advanced far beyond their origins. Originally developed as treatments for type 2 diabetes, they have become one of the most influential forces reshaping consumer behaviour, healthcare delivery and pharmaceutical strategy.

This shift is now visible far beyond the clinic. Appetite-modifying medications such as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro), along with emerging oral and multi-agonist therapies, are influencing everything from food purchasing to health system planning.

Their impact reflects a shift in clinical innovation, changing patient expectations and heightening system level pressures. This all indicates that a new era in metabolic health is already upon us.

One of the clearest indicators of GLP-1s’ influence appears on the high street.
Major brands have begun adjusting product strategies in response to sustained reductions in appetite and altered dietary preferences among GLP-1 users.

McDonald’s has explored new protein-leaning menu items and smaller portion formats, reflecting observed patterns such as reduced snacking and sugary drink consumption, resulting in lower demand for high sugar products.

Similar trends are emerging at Greggs, where evolving consumption behaviours have prompted shifts in product mix.

These changes highlight a broader point: GLP-1 therapies are having measurable knock-on effects on industries and other parts of life that are traditionally far removed from healthcare. For pharma, monitoring human behaviour can reveal far more than trial-defined outcomes and must be considered.

As GLP-1 behaviours spill into mainstream consumer life, patients will present with new expectations, altered eating patterns and different motivations for treatment.  Clinicians must adapt how they assess lifestyle context, guide long term adherence and anticipate challenges shaped as much by real world behaviour as by biology.

This all ties into a much bigger narrative. The UK health system is undergoing its own transformation.

Since 2025, NHS England has been rolling out tirzepatide through primary care under NICE recommendations. It argued that integrating pharmacotherapy into broader obesity care pathways could relieve pressure on specialist clinics.

As demand surges, prescriptions in England have increased dramatically since 2020, far outstripping system capacity.

Yet access remains inconsistent. Funding constraints have also created disparities in who can benefit from treatment across regions.

Meanwhile, private access continues to expand, raising equity concerns as millions look to obtain GLP-1s through alternative routes while the NHS plans a more gradual, tightly prioritised rollout.

For HCPs, this rising demand and uneven access could mean greater pressure on primary care teams, who must manage fast-growing patient enquiries, eligibility assessments and follow-up demands within a system not yet scaled for widespread obesity pharmacotherapy. We have seen the impact of this on a larger scale already with COVID-19.

Regional funding variation and the rapid growth of private prescribing also create inconsistent patient expectations, leaving clinicians to navigate equity concerns and differing access routes while still ensuring safe, evidence-based care.

According to DiCE, around 2.5 million people each month were accessing GLP-1s privately by the end of 2025.

The current system for supporting people with obesity was not built for a future in which many patients stay on weight-loss medicines for years.

As more people start GLP-1 treatments, HCPs will increasingly face patients who need ongoing guidance, realistic expectations and consistent follow-up. This means successful treatment will depend as much on everyday clinical support as on the drug itself.

The NHS is not yet fully set up for the volume of monitoring, lifestyle counselling and digital tracking that long term use requires.

With demand rising faster than the system can adapt, GPs and nurses are likely to experience more pressure in managing eligibility, access and long term care, making better coordination between public health teams, primary care and local services essential.

Clinicians will also face new professional demands that extend beyond prescribing.  Many will require updated training and clearer guidance on risk assessment, particularly as patients present with evolving medical conditions that require a shift in safety considerations.

The emotional side of care will also grow. HCPs will need to manage heightened expectations, misconceptions about effortless weight loss and the wider psychological impact of rapid physical change.

Multidisciplinary support will become increasingly important, requiring collaboration between dietitians, pharmacists, behavioural change specialists and mental health services.

The responsibilities can intensify ten-fold. HCPs must learn to navigate unfamiliar dosing histories, safety risks and gaps in monitoring for patients arriving from less-regulated routes.

Meanwhile, the expansion of digital tools and patient-generated data means clinicians may soon face a heavier administrative load as they interpret remote check-ins, weight tracking apps and symptom monitoring platforms.

Together, these pressures signal a future in which the role of the clinician is broader, more complex and more interconnected, requiring not only medical expertise but new skills, new workflows and a system designed to support them.

For HCPs, adherence remains one of the biggest challenges. Many patients stop treatment because of access barriers or misunderstandings about how long therapy is needed.
The arrival of oral GLP-1 medicines may make long-term use easier, but it also means more patients could start treatment, increasing the frontline workload.
This shift reinforces the need for simple, patient centred support systems that clinicians can rely on, from digital check-ins to practical diet and lifestyle resources, so patients can stay on track and avoid relapse.

As GLP-1 therapies expand into areas such as heart health improvement, sleep apnoea and liver disease, HCPs will need to integrate these medicines into broader chronic disease management rather than treating them as a single purpose weight loss intervention.

Clinicians will face more complex conversations about benefits, risks and long term planning as more options become available and more patients become eligible.

GLP-1 therapies are redefining obesity care across the NHS, influencing daily practice, patient expectations and wider conversations about prevention.

For HCPs, the coming years will mean adapting how they work, supported by clearer pathways and stronger systems that enable these medicines to deliver sustained, meaningful benefit.